Psychedelic-Based Therapeutics for Generalized Anxiety Disorder (GAD) – Interview with Robert Barrow, CEO, MindMed Xtalks Life Science Podcast

In this episode, Ayesha spoke with Robert Barrow, CEO and Board Director at MindMed, a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. The company is developing innovative psychedelic-based product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders.Mr. Barrow is an accomplished pharmaceutical executive and clinical pharmacologist with over a ...